Progress of Research on Immune-related Pneumonia in Non-small Cell Lung Cancer
In recent years, immunotherapy has made a breakthrough in the field of non-small cell lung cancer, reshaping the pattern of lung cancer treatment. However, with the wide application of immunotherapy in clinical practice, immune-related adverse events have attracted increasing attention. Immune pneum...
Main Authors: | WANG Tianming, ZHANG Liang, CHENG Ying |
---|---|
Format: | Article |
Language: | zho |
Published: |
Magazine House of Cancer Research on Prevention and Treatment
2023-08-01
|
Series: | Zhongliu Fangzhi Yanjiu |
Subjects: | |
Online Access: | http://www.zlfzyj.com/EN/10.3971/j.issn.1000-8578.2023.23.0075 |
Similar Items
-
Future Prospects of Immunotherapy in Non-Small-Cell Lung Cancer Patients: Is There Hope in Other Immune Checkpoints Targeting Molecules?
by: Natalia Krzyżanowska, et al.
Published: (2022-03-01) -
Newly diagnosed non‐small cell lung cancer with interstitial lung abnormality: Prevalence, characteristics, and prognosis
by: Min Zhu, et al.
Published: (2023-07-01) -
Exploring histological predictive biomarkers for immune checkpoint inhibitor therapy response in non–small cell lung cancer
by: Uiju Cho, et al.
Published: (2024-03-01) -
Factors Predictive of Primary Resistance to Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer
by: Yiqing Huang, et al.
Published: (2023-05-01) -
Immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer: A review
by: Yuxuan Hao, et al.
Published: (2022-08-01)